UPDATE 1-Auxilium Pharma Q4 revenue beats Street, shares up

* Q4 prelim rev $61.8 mln vs est $57 mln

* Shares up as much as 17 pct

Jan 10 (BestGrowthStock) – Auxilium Pharmaceuticals Inc (AUXL.O: )
reported fourth-quarter revenue that beat market estimates,
helped by higher sales across all its segments, sending its
shares up as much as 17 percent.

For the fourth quarter, the company reported preliminary
revenue of $61.8 million while analysts on average were
expecting revenue of $57 million, according to Thomson Reuters
I/B/E/S.

For 2011, the company expects to report $55-$67 million in
revenue from its hand disorder drug, Xiaflex, which was
launched in February.

Auxillium, which will be attending the J.P. Morgan
Healthcare Conference in San Francisco on Tuesday, said it
believes Xiaflex may become a blockbuster drug.

The company’s shares, which have lost 14 percent since it
reported third-quarter results in November, were up 13 percent
at $23.17 on Monday on Nasdaq after touching a high of $24.14.
(Reporting by Anand Basu in Bangalore; Editing by Joyjeet
Das)